Estimated GFR decline as a surrogate end point for kidney failure: A post hoc analysis from the reduction of end points in non-insulin-dependent diabetes with the Angiotensin II Antagonist Losartan (RENAAL) study and Irbesartan Diabetic Nephropathy Trial (IDNT)

Hiddo J. Lambers Heerspink, Misghina Weldegiorgis, Lesley A. Inker, Ron Gansevoort, Hans Henrik Parving, Jamie P. Dwyer, Hasi Mondal, Josef Coresh, Tom Greene, Andrew S. Levey, Dick De Zeeuw

Research output: Contribution to journal › Article › peer-review

44 Scopus citations

Fingerprint

Dive into the research topics of 'Estimated GFR decline as a surrogate end point for kidney failure: A post hoc analysis from the reduction of end points in non-insulin-dependent diabetes with the Angiotensin II Antagonist Losartan (RENAAL) study and Irbesartan Diabetic Nephropathy Trial (IDNT)'. Together they form a unique fingerprint.

Medicine & Life Sciences